{"nctId":"NCT00240331","briefTitle":"AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)","startDateStruct":{"date":"2003-01"},"conditions":["Renal Failure"],"count":2776,"armGroups":[{"label":"Rosuvastatin 10mg","type":"EXPERIMENTAL","interventionNames":["Drug: 10mg Rosuvastatin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"10mg Rosuvastatin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects with end-stage renal failure aged 50-80 years, who have received regular haemodialysis treatment for at least 3 months\n\nExclusion Criteria:\n\n* Subjects will have no underlying condition that is expected to limit survival to less than 1 year and is also unrelated to end-stage renal disease (ESRD). Subjects should not have received a statin therapy within the past 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"396","spread":null},{"groupId":"OG001","value":"408","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Randomised Participants That Died From Any Cause.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"636","spread":null},{"groupId":"OG001","value":"660","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"614","spread":null},{"groupId":"OG001","value":"645","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Randomised Participants That Died From Cardiovascular Cause","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null},{"groupId":"OG001","value":"324","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Randomised Participants That Died From Non Cardiovascular Cause","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"258","spread":null},{"groupId":"OG001","value":"256","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"390","spread":null},{"groupId":"OG001","value":"360","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations).","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1140},"commonTop":["Diarrhoea","Bronchitis","Arteriovenous Fistula Site Complication","Cough","Nasopharyngitis"]}}}